A Phase 1b Open-label Study to Investigate theSafety and Pharmacokinetics of Administration ofSubcutaneous Blinatumomab for the Treatment ofadults with Relapsed or Refractory B cell PrecursorAcute Lymphoblastic Leukemia (R/R B-ALL)
MD Anderson Study Status
The study aims to evaluate the safety, efficacy, and tolerability of subcutaneous (SC) blinatumomab for treatment of Acute Lymphoblastic Leukemia (ALL) and to determine the maximum tolerated dose (MTD), and recommended phase 2 dose (RP2D) of SC administered blinatumomab.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
B Cell Precursor Acute Lymphoblastic Leukemia
For general questions about clinical trials: